Dendreon (DNDN) drop could forecast Pall over Cell Therapy companies)
November 3rd, 2011
No comments
The unexpected rise in Provenge’s cost of goods and sales of the prostate cancer therapy Read more…
Categories: Cell Therapy Companies, Dendreon (DNDN), Opinion
